The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments

References

• Friman V, Winqvist O, Blimark C, et al. Secondary immunodeficiency in lymphoproliferative malignancies. Hematol Oncol. 2016;34(3):121–132. doi: 10.1002/hon.2323
   PubMed Web of Science ®Google Scholar
• Mouthon L, Fermand J-P, Gottenberg J-E. Management of secondary immune deficiencies: what is the role of immunoglobulins? Curr Opin Allergy Clin Immunol. 2013;13:S56–S67. doi: 10.1097/01.all.0000433132.16436.b5
   PubMed Web of Science ®Google Scholar
• Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2012;13(2):106–111. doi: 10.1016/j.clml.2012.11.011
   PubMed Web of Science ®Google Scholar
• De Angelis F, Tosti ME, Capria S, et al. Risk of secondary hypogammaglobulinaemia after rituximab and fludarabine in indolent non-Hodgkin lymphomas: a retrospective cohort study. Leuk Res. 2015;39(12):1382–1388. doi: 10.1016/j.leukres.2015.10.013
   PubMed Web of Science ®Google Scholar
• Dhalla F, Misbah SA. Secondary antibody deficiencies. Curr Opin Allergy Clin Immunol. 2015;15(6):505–513. doi: 10.1097/ACI.0000000000000215
   PubMed Web of Science ®Google Scholar
• Hallek M. Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90(5):446–460. doi: 10.1002/ajh.23979
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v78–v84. doi: 10.1093/annonc/mdv303
   PubMed Web of Science ®Google Scholar
• EMA. Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) EMA/CHMP/BPWP/94038/2007 Rev. 4 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/12/WC500136433.pdf.
   Google Scholar
• EMA. Core summary of product characteristics for human normal immunoglobulin for subcutaneous and intramuscular administration EMA/CHMP/BPWP/410415/2011 rev 1 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500184870.pdf.
   Google Scholar
• Lachance S, Christofides AL, Lee JK, et al. A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia. Curr Oncol. 2016;23(1):42. doi: 10.3747/co.23.2810
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. Blood. 2018 Mar 14. DOI:10.1182/blood-2017-09-806398. PubMed PMID: 29540348.
   Web of Science ®Google Scholar
• Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017;139(3):S1–S46. DOI:10.1016/j.jaci.2016.09.023.
   PubMed Web of Science ®Google Scholar
• de Souza KJ, Ferro RS, Prestes-Carneiro LE, et al. Infectious diseases and immunological markers associated with patients with non-Hodgkin lymphoma treated with rituximab. Immunopharmacol Immunotoxicol. 2018 Feb;40(1):13–17. DOI:10.1080/08923973.2017.1392562 PubMed PMID: 29094629.
   PubMed Web of Science ®Google Scholar
• Benbrahim O, Viallard J-F, Choquet S, et al. A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency. Eur J Haematol. 2018;101(1):48–56. DOI:10.1111/ejh.13078.
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006 Aug 15;145(4):247–254. PubMed PMID: 16908915. doi: 10.7326/0003-4819-145-4-200608150-00004
   PubMed Web of Science ®Google Scholar
• Compagno N, Cinetto F, Semenzato G, et al. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients. Haematologica. 2014;99(6):1101–1106. doi: 10.3324/haematol.2013.101261
   PubMed Web of Science ®Google Scholar
• Shankar T, Gribowicz J, Crespo M, et al. Subcutaneous IgG replacement therapy is safe and well tolerated in lung transplant recipients. Int Immunopharmacol. 2013;15(4):752–755. doi: 10.1016/j.intimp.2013.02.021
   PubMed Web of Science ®Google Scholar
• Reiser M, Borte M, Huscher D, et al. Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: long-term data of the SIGNS study. Eur J Haematol. 2017 Aug;99(2):169–177. DOI:10.1111/ejh.12900. PubMed PMID: 28467615.
   PubMed Web of Science ®Google Scholar
• Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol. 2006 Dec;6(6):434–442. PubMed PMID: 17088648. doi: 10.1097/01.all.0000246619.49494.41
   PubMed Web of Science ®Google Scholar
• Hammarstrom L, Samuelsson J, Grimfors G. Subcutaneous gammaglobulin for patients with secondary hypogammaglobulinaemia. Lancet. 1995 Feb 11;345(8946):382–383. PubMed PMID: 7531264.
   PubMed Web of Science ®Google Scholar
• Kobrynski L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics. 2012;6:277–287. PubMed PMID: 22956859.
   PubMedGoogle Scholar
• Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006 Jan;26(1):65–72. PubMed PMID: 16418804. doi: 10.1007/s10875-006-8905-x
   PubMed Web of Science ®Google Scholar
• Abolhassani H, Sadaghiani MS, Aghamohammadi A, et al. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol. 2012 Dec;32(6):1180–1192. PubMed PMID: 22730009. doi: 10.1007/s10875-012-9720-1
   PubMed Web of Science ®Google Scholar
• Shapiro RS. Why I use subcutaneous immunoglobulin (SCIG). J Clin Immunol. 2013 Jan;33(Suppl 2):S95–S98. PubMed PMID: 23264027. doi: 10.1007/s10875-012-9853-2
   PubMed Web of Science ®Google Scholar
• Misbah S, Sturzenegger MH, Borte M, et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol. 2009 Dec;158 Suppl 1:51–59. PubMed PMID: 19883424. doi: 10.1111/j.1365-2249.2009.04027.x
   PubMed Web of Science ®Google Scholar
• Bienvenu B, Cozon G, Hoarau C, et al. Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort “visages”. Orphanet J Rare Dis. 2016 Jun 22;11(1):83. PubMed PMID: 27334100. doi: 10.1186/s13023-016-0452-9
   PubMed Web of Science ®Google Scholar
• Orange JS, Grossman WJ, Navickis RJ, et al. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137(1):21–30. doi: 10.1016/j.clim.2010.06.012
   PubMed Web of Science ®Google Scholar
• Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125(6):1354–1360. doi: 10.1016/j.jaci.2010.02.040
   PubMed Web of Science ®Google Scholar
• Hoffmann F, Grimbacher B, Thiel J, et al. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res. 2010 Jun 28;15(6):238–245. PubMed PMID: 20696632.
   PubMed Web of Science ®Google Scholar
• Boughton BJ, Jackson N, Lim S, et al. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haematol. 1995 Mar;17(1):75–80. PubMed PMID: 7621634. doi: 10.1111/j.1365-2257.1995.tb00322.x
   PubMedGoogle Scholar
• Bunch C. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia: a randomized, controlled clinical trial. N Engl J Med. 1988;319(14):902–907. doi: 10.1056/NEJM198810063191403
   PubMed Web of Science ®Google Scholar
• Chapel H, Dicato M, Gamm H, et al. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes. Br J Haematol. 1994;88(1):209–212. doi: 10.1111/j.1365-2141.1994.tb05002.x
   PubMed Web of Science ®Google Scholar
• Chapel HM, Lee M, Hargreaves R, et al. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK group for immunoglobulin replacement therapy in multiple myeloma. Lancet. 1994 Apr 30;343(8905):1059–1063. PubMed PMID: 7909099. doi: 10.1016/S0140-6736(94)90180-5
   PubMed Web of Science ®Google Scholar
• Griffiths H, Brennan V, Lea J, et al. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood. 1989 Feb;73(2):366–368. PubMed PMID: 2492832.
   PubMed Web of Science ®Google Scholar
• Molica S, Musto P, Chiurazzi F, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica. 1996;81(2):121–126.
   PubMed Web of Science ®Google Scholar
• Raanani P, Gafter-Gvili A, Paul M, et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma. 2009;50(5):764–772. doi: 10.1080/10428190902856824
   PubMed Web of Science ®Google Scholar
• Park S, Jung CW, Jang JH, et al. Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma. Transpl Infect Dis. 2015;17(5):679–687. DOI:10.1111/tid.12424.
   PubMed Web of Science ®Google Scholar
• Windegger TM, Lambooy CA, Hollis L, et al. Subcutaneous immunoglobulin therapy for hypogammaglobulinemia secondary to malignancy or related drug therapy. Transfus Med Rev. 2017;31(1):45–50. doi: 10.1016/j.tmrv.2016.06.006
   PubMed Web of Science ®Google Scholar
• Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies – a prospective, multi-national study. J Clin Immunol. 2006 Mar;26(2):177–185. PubMed PMID: 16758340. doi: 10.1007/s10875-006-9002-x
   PubMed Web of Science ®Google Scholar
• Cherin P, Marie I, Michallet M, et al. Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence. Autoimmun Rev. 2016;15(1):71–81. doi: 10.1016/j.autrev.2015.09.002
   PubMed Web of Science ®Google Scholar
• Itkin YM, Trujillo TC. Intravenous immunoglobulin-associated acute renal failure: case series and literature review. Pharmacotherapy. 2005;25(6):886–892. doi: 10.1592/phco.2005.25.6.886
   PubMed Web of Science ®Google Scholar
• Epstein JS, Zoon KC. Important drug warning: immune globulin intravenous (human)(IGIV) products. Neonatal Netw. 2000;19(2):60.
   PubMedGoogle Scholar
• Jurlander J, Geisler CH, Hansen MM. Treatment of hypogammaglobulinemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin. Eur J Haematol. 1994;53(2):114–118. doi: 10.1111/j.1600-0609.1994.tb01874.x
   PubMed Web of Science ®Google Scholar
• Visentin A, Compagno N, Cinetto F, et al. Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy. Haematologica. 2015;100(12):e515–e518. DOI:10.3324/haematol.2015.126763.
   PubMed Web of Science ®Google Scholar
• Raanani P, Gafter-Gvili A, Paul M, et al. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2008;27(5):770–781. doi: 10.1200/JCO.2008.16.8450
   PubMed Web of Science ®Google Scholar